Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients
Breast Cancer, Radiotherapy; Complications
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Mastectomy, Reconstruction, Radiation therapy, Conventional fractionation, Hypofractionation, Complication
Eligibility Criteria
Inclusion Criteria:
- Female patient who underwent mastectomy for invasive breast cancer
- Patients who have undergone breast reconstruction after mastectomy or who have inserted a tissue expander
- (y)p patients with stage IIIA or lower (excluding T4 and N3 patients) who need adjuvant radiation therapy
- Eastern Cooperative Oncology Group Performance ≤ 2
- Age ≥ 19 years
- Patients who agreed to participate in the study
Exclusion Criteria:
- Patients who already had implants at the time of diagnosis of breast cancer or who have already undergone reconstructive surgery
- Patients who underwent reconstruction after partial resection or breast conserving surgery rather than mastectomy
- Patients who are using or planning to use an air expander
- Patients receiving radiation therapy for salvage or palliative purposes
- Patients with distant metastases at the time of diagnosis
- Patients who are scheduled to undergo concurrent chemoradiation therapy
- Patients with bilateral breast cancer
- Male breast cancer patients
- Patients who have previously received radiation therapy for the ipsilateral breast or supraclavicular area
- Patients with history of cancers other than thyroid cancer, intraepithelial cancer of the cervix, or skin cancer
- Patients diagnosed with ductal breast carcinoma in situ, lobular carcinoma in situ, phyllodes, metaplastic cancer, or other benign tumors based on histological diagnosis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Hypofractionation
Conventional Fractionation
For the cumulative total dose of 39-45.9 Gy to the chest wall, a daily dose of 2.5-3.0 Gy is administered 13-17 fractions. Should be started within 3 months of completion of mastectomy or chemotherapy. Clinical target volume (CTV) may include regional lymph nodes. If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines.
For the cumulative total dose of 45-50.4 Gy to the chest wall, a daily dose of 1.8-2.0 Gy is administered 23-28 fractions. Should be started within 3 months of completion of mastectomy or chemotherapy. Clinical target volume (CTV) may include regional lymph nodes. If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines.